Sumatriptan
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Sumatriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Sumatriptan is a triptan-class medicine generally used for the acute treatment of migraine and cluster headache. The TxGNN model predicts a possible link to Migraine with Brainstem Aura, but the underlying evidence — 0 clinical trials and 19 publications — actually points to a known mechanistic contraindication rather than a genuine repurposing opportunity, and the recommended action is therefore to Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this Evidence Pack (Sumatriptan is generally used for acute migraine and cluster headache) |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 |
| UK Market Status | Not marketed (per this Evidence Pack — see note in Conclusion) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Sumatriptan is not available in the structured Evidence Pack. Based on established pharmacological knowledge, Sumatriptan is a selective 5-HT1B/1D receptor agonist (“triptan”), long used for acute migraine and cluster headache treatment. It works through cranial vasoconstriction and inhibition of inflammatory neuropeptide release from the trigeminovascular system.
Migraine with brainstem aura (formerly known as basilar-type migraine) is a rare migraine subtype in which aura symptoms arise from transient dysfunction of the posterior (vertebrobasilar) circulation, rather than the cortical mechanisms implicated in typical migraine. Although this subtype falls within the same broad “migraine” disease family that Sumatriptan already treats, its distinct vascular territory means the same vasoconstrictive mechanism that makes triptans effective in common migraine carries a theoretical risk of provoking brainstem or posterior-circulation ischaemia in this specific subtype.
For this reason, the International Headache Society (ICHD) and most clinical guidelines classify migraine with brainstem aura as a relative or absolute contraindication for triptan-class drugs, rather than a candidate for indication expansion. The TxGNN model has likely generated this prediction based on surface-level disease-family similarity (both are migraine subtypes) without capturing this safety-critical distinction. This prediction should therefore be interpreted as a safety signal flag, not a genuine repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25600718 | 2015 | Review (Guideline/Evidence Assessment) | Headache | American Headache Society evidence assessment of acute migraine pharmacotherapies, including triptans |
| 1313746 | 1992 | RCT | Cephalalgia | Double-blind, placebo-controlled trial of oral sumatriptan 200 mg in acute migraine with aura |
| 25841032 | 2015 | Cohort/Comparative | Neurology | Found reduced efficacy of sumatriptan in migraine with aura versus migraine without aura |
| 25841027 | 2015 | Commentary | Neurology | Editorial discussing whether aura presence predicts migraine severity and triptan treatment response |
| 33567890 | 2021 | RCT | Cephalalgia | Early sumatriptan treatment tested against PACAP38-induced experimental migraine attacks |
| 21469920 | 2011 | Review | Expert Review of Neurotherapeutics | Needle-free subcutaneous sumatriptan approved for migraine with/without aura and cluster headache |
| 8559405 | 1996 | Clinical study | Neurology | Examines subcutaneous sumatriptan effects specifically on the migraine aura phase |
| 31135819 | 2019 | Mechanistic/Imaging study | JAMA Neurology | Central 5-HT1B receptor binding during sumatriptan treatment of migraine attacks |
| 23657930 | 2014 | RCT (small) | Phytotherapy Research | Compared ginger versus sumatriptan in common migraine (without aura) |
| 39391443 | 2024 | Case Report | Cureus | Rare case of migraine with aura accompanied by myoclonus |
UK Market Information
Sumatriptan is recorded as not marketed in this Evidence Pack, with 0 marketing authorisations listed. No product-level licence data is currently available.
Safety Considerations
Key Warning (derived from repurposing rationale): Migraine with brainstem aura is widely regarded as a relative or absolute contraindication for triptan-class drugs, including Sumatriptan, due to the theoretical risk of inducing vasoconstriction in the posterior (vertebrobasilar) circulation. This candidate indication should not be pursued without an explicit, dedicated safety re-evaluation.
For general safety information, please refer to the SmPC and BNF. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack’s own mechanistic analysis identifies this as a mechanistic conflict, not mechanistic support — migraine with brainstem aura is conventionally treated as a contraindication for triptans, not a repurposing target. There are no clinical trials, and the literature (though moderately extensive) does not support new-indication use; if anything, it documents reduced triptan efficacy in aura subtypes. A “Blocking” data gap also exists for regulatory label warnings/contraindications (DG001).
To proceed, the following is needed:
- Full MHRA-approved SmPC for Sumatriptan, including explicit contraindication wording for basilar-type/brainstem-aura migraine (resolves DG001, Blocking)
- Confirmed mechanism of action data via DrugBank (resolves DG002, High)
- A dedicated pharmacovigilance/safety review before any further consideration of this candidate — this is not a standard repurposing evaluation pathway given the contraindication signal
- Verification of UK market status: this Evidence Pack shows “Not marketed,” which should be reconciled against known Sumatriptan products (e.g., Imigran) in the MHRA product database before this record is relied upon
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.